Clinical Lung Cancer

Top Research Topics at Clinical Lung Cancer?

Clinical Lung Cancer primarily tackles Lung cancer, Internal medicine, Oncology, Chemotherapy and Surgery. Clinical Lung Cancer explores topics in Lung cancer which can be helpful for research in disciplines like Cancer, Adenocarcinoma, Cancer research and Radiation therapy. Topics in Adenocarcinoma were tackled in line with various other fields like Carcinoma, Pathology and Lung.

Clinical Lung Cancer focuses on Cancer research as well as the interrelated topic of Crizotinib. Internal medicine research discussed connects with the study of Gastroenterology. The research on Oncology tackled can also make contributions to studies in the areas of Survival rate and Docetaxel.

Clinical Lung Cancer connects research in Chemotherapy with the related topic of Regimen. In the Surgery research discussed, Stage (cooking), Retrospective cohort study and Randomized controlled trial are all tackled. The concepts on Epidermal growth factor receptor presented in Clinical Lung Cancer can also apply to other research fields, including Tyrosine kinase and Tyrosine-kinase inhibitor.

• Lung cancer (94.87%)
• Internal medicine (62.37%)
• Oncology (49.87%)

What are the most cited papers published in the journal?

• Exosomal microRNA: A Diagnostic Marker for Lung Cancer (1007 citations)
• Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. (335 citations)
• An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer (241 citations)

Research areas of the most cited articles at Clinical Lung Cancer:

The journal publications primarily tackle Lung cancer, Internal medicine, Oncology, Surgery and Chemotherapy. In addition to Lung cancer research, the most cited articles aim to explore topics under Cancer, Epidermal growth factor receptor, Adenocarcinoma, Survival rate and Carcinoma. While Oncology is the focus of the most cited publications, it also provides insights into the studies of Adverse effect, Randomized controlled trial, Survival analysis and Confidence interval.

What topics the last edition of the journal is best known for?

• Cancer
• Internal medicine
• Gene

The previous edition focused in particular on these issues:

Clinical Lung Cancer mainly deals with areas of study such as Lung cancer, Internal medicine, Oncology, Lung and Cancer research. The studies in Lung cancer featured incorporate elements of Cancer, Adenocarcinoma, Immunotherapy and Hazard ratio, Confidence interval. The work on Internal medicine addressed in it expands to the thematically related Gastroenterology.

Clinical Lung Cancer facilitates discussions on Oncology that incorporate concepts from other fields like Targeted therapy, Clinical endpoint, Radiation therapy and Epidermal growth factor receptor. It focuses on Lung but sometimes tackles the closely related topic of Radiology which is concerned with Metastasis. Clinical Lung Cancer holds forums on Cancer research that merges themes from other disciplines such as Crizotinib and Alectinib.

The most cited articles from the last journal are:

• NTRK Fusion-positive Non–small-cell Lung Cancer: The Diagnosis and Targeted Therapy (9 citations)
• The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. (8 citations)
• Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. (7 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Clinical Lung Cancer (based on the number of publications) are:

• Chandra P. Belani (87 papers) absent at the last edition,
• David R. Gandara (84 papers) published 9 papers at the last edition, 8 more than at the previous edition,
• Corey J. Langer (54 papers) published 2 papers at the last edition, 1 more than at the previous edition,
• Primo N. Lara (50 papers) published 3 papers at the last edition,
• Roy S. Herbst (37 papers) published 4 papers at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Clinical Lung Cancer (based on the number of publications) are:

• University of Texas MD Anderson Cancer Center (107 papers) published 18 papers at the last edition, 10 more than at the previous edition,
• University of California, Davis (94 papers) published 12 papers at the last edition, 9 more than at the previous edition,
• University of Pittsburgh (48 papers) published 5 papers at the last edition, 3 more than at the previous edition,
• Stanford University (45 papers) published 8 papers at the last edition, 6 more than at the previous edition,
• University of Pennsylvania (42 papers) published 3 papers at the last edition, 1 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 6.50% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 24.78% were posted by at least one author from the top 10 institutions publishing in the journal. Another 9.57% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 16.09% of all publications and 49.57% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Clinical Approach to Lung Cancer treatment in Indiana